Redeye gives its view on the Q-linea third quarter report published earlier this morning. The activity behind the scenes has been intense in preparation ahead of the pivotal trial for ASTar®. The financial outcome of the quarter was uneventful, even if the costs were slightly higher than expected. As we can see, the progress is much in line with what is expected at this point. Overall, we still have a positive view of the progress made and remain optimistic about the long-term Q-linea case. We are marginally adjusting our costs for the current year while leaving our other estimates unchanged for the coming years. We maintain our valuation and a fair value of the share at SEK 175 per share.